Fitting with this hypothesis, the two commonly used anti-mouse CD40 agonist antibody clones, FGK45 and IC10, bind the CD40L binding site of CD40 and depend on FcR crosslinking and both show potent anti-tumor efficacy in preclinical mouse models [24]. Here, CD40 is linked to neoplasm.